secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001127537-24-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M
----------------------------------------------------------------

- Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).
- Net loss $13.7M ($0.36 per share) versus $15.9M ($0.42) in Q1 2023; Adjusted EBITDA loss $8M vs $11.2M.
- Gross margin 75% (vs 73% YoY); FY 2024 revenue guidance reaffirmed $81M-$84M; operating expenses guidance tightened to $127M-$129M.
- Cash and equivalents $120.4M; clinical milestones: first AeriSeal CONVERT II patient and first Japanese Zephyr post-approval patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/0001127537-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000045/lung-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001127537-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer